Rivastigmine is a cholinesterase inhibitor indicated for treatment of mild, moderate, and severe dementia of the Alzheimer’s type (AD), among other approved uses. It is available as capsules and transdermal patches for oral use. MedsAcross supplies Rivastigmine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
EXELON PATCH is an acetylcholinesterase inhibitor indicated for treatment of: • Mild, moderate, and severe dementia of the Alzheimer’s type (AD). • Mild-to-moderate dementia associated with Parkinson’s disease (PD).
Source: US FDA prescribing information
Although the precise mechanism of action of rivastigmine is unknown, it is thought to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase. The effect of rivastigmine may lessen as the disease process advances and fewer cholinergic neurons remain functionally intact. There is no evidence that rivastigmine alters the course of the underlying dementing process.
Source: US FDA prescribing information
• Apply patch on intact skin for a 24-hour period, replace with a new patch every 24 hours. • Initial Dose: Initiate treatment with 4.6 mg/24 hours EXELON PATCH. • Dose Titration: After a minimum of 4 weeks, if tolerated, increase dose to 9.5 mg/24 hours, which is the minimum effective dose. Following a minimum additional 4 weeks, may increase dosage to maximum dosage of 13.3 mg/24 hours. • Mild-to-Moderate Alzheimer’s Disease and Parkinson’s Disease Dementia: EXELON PATCH 9.5 mg/24 hours or 13.3 mg/24 hours once daily. • Severe Alzheimer’s Disease: EXELON PATCH 13.3 mg/24 hours once daily. • For treatment interruption longer than 3 days, retitrate dosage starting at 4.6 mg per 24 hours. • Consider dose adjustments in patients with: o Mild-to-moderate hepatic impairment o Low (less than 50 kg) body weight
Source: US FDA prescribing information
EXELON PATCH is contraindicated in patients with: • known hypersensitivity to rivastigmine, other carbamate derivatives, or other components of the formulation • previous history of application-site reactions with rivastigmine transdermal patch suggestive of allergic contact dermatitis. Isolated cases of generalized skin reactions have been described in postmarketing experience. • Known hypersensitivity to rivastigmine, other carbamate derivatives, or other components of the formulation. • History of application-site reactions with rivastigmine transdermal patch suggestive of allergic contact dermatitis.
Source: US FDA prescribing information
• Hospitalization and, rarely, death have been reported due to application of multiple patches at same time. Ensure patients or caregivers receive instruction on proper dosing and administration. • Gastrointestinal Adverse Reactions: May include significant nausea, vomiting, diarrhea, anorexia/decreased appetite, and weight loss, and may necessitate treatment interruption. Dehydration may result from prolonged vomiting or diarrhea and can be associated with serious outcomes. • Application-site reactions may occur with the patch form of rivastigmine. Discontinue treatment if application-site reactions spread beyond the patch size, if there is evidence of a more intense local reaction (e.g., increasing erythema, edema, papules, vesicles), and if symptoms do not significantly improve within 48 hours after patch removal.
Source: US FDA prescribing information
The following clinically significant adverse reactions are described below and elsewhere in the labeling: • Gastrointestinal Adverse Reactions • Skin Reactions • Other Adverse Reactions from Increased Cholinergic Activity Most common adverse reactions (less than 5% and higher than with placebo): Nausea, vomiting, and diarrhea.
Source: US FDA prescribing information
Concomitant use with metoclopramide, beta-blockers, or cholinomimetics and anticholinergic medications is not recommended. Metoclopramide Due to the risk of additive extra-pyramidal adverse reactions, the concomitant use of metoclopramide and EXELON PATCH is not recommended. Cholinomimetic and Anticholinergic Medications EXELON PATCH may increase the cholinergic effects of other cholinomimetic medications and may also interfere with the activity of anticholinergic medications (e.g., oxybutynin, tolterodine). Concomitant use of EXELON PATCH with medications having these pharmacologic effects is not recommended unless deemed clinically necessary. Beta-Blockers Additive bradycardic effects resulting in syncope may occur when EXELON is used concomitantly with beta-blockers, especially cardioselective beta-blockers (including atenolol).
Source: US FDA prescribing information
Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F and 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
10 presentations of Rivastigmine, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Rivastigmine 1.5 mg capsuleOralGeneric name | — | US FDA | Available on request |
| Rivastigmine 3 mg capsuleOralGeneric name | — | US FDA | Available on request |
| Rivastigmine 4.5 mg capsuleOralGeneric name | — | US FDA | Available on request |
| Rivastigmine 6 mg capsuleOralGeneric name | — | US FDA | Available on request |
| Rivastigmine 13.3 mg/24 hours transdermal patchTransdermalGeneric name | — | US FDA | Available on request |
| Rivastigmine 9.5 mg/24 hours transdermal patchTransdermalGeneric name | — | US FDA | Available on request |
| Rivastigmine 4.6 mg/24 hours transdermal patchTransdermalGeneric name | — | US FDA | Available on request |
| Exelon 4.6 mg/24 hours transdermal patchTransdermal | Sandoz | US FDA | Available on request |
| Exelon 9.5 mg/24 hours transdermal patchTransdermal | Sandoz | US FDA | Available on request |
| Exelon 13.3 mg/24 hours transdermal patchTransdermal | Sandoz | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Rivastigmine in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 10 presentations of Rivastigmine and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Rivastigmine, including Exelon.
Yes. The US FDA first approved Rivastigmine on 21 April 2000, according to Drugs@FDA.
Yes. Rivastigmine has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Rivastigmine is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Rivastigmine is classified under ATC code N06DA03 (Rivastigmine).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.